Work

Supplementary Figure 3 from Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy

Year: 2026

Type: supplementary-materials

Abstract: Figure S3. Antigen expression and HER2 knock-down in a panel of cancer cell lines and additional Jurkat T cell reporter activation (NFAT-GFP) assays in co-culture with 293T* (HER2 KD) cells transfected with tumor associated antigens (related to Figure 2C, 2D.

DOI: 10.1158/0008-5472.32707329

Authors: Rogelio A. Hernández-López, Tapio Kesti, Anna R. Mäkelä, Zhe Zhao, Wei Yu, Yurie Tonai, Hector J. Monzo, Kerttu Kalander, Sirpa Leppä, Päivi M. Ojala, Wendell A. Lim, Kalle Saksela

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7165016971

Cites:

Cited by:

Related to: 10